歡迎光臨源葉生物,登錄 | 注冊(cè) |
當(dāng)前位置: 首頁(yè) > 小分子抑制劑 > Angiogenesis > Naquotinib

瀏覽歷史

S81341

Naquotinib

源葉(MedMol) ≥96%
  • 英文名:
  • Naquotinib
  • 別名:
  • CAS號(hào):
  • 1448232-80-1
  • 分子式:
  • C30H42N8O3
  • 分子量:
  • 562.7063
品牌貨號(hào)產(chǎn)品規(guī)格價(jià)格(RMB) 庫(kù)存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購(gòu)物車...
源葉(MedMol) S81341-5mg ≥96% ¥677.00元 10 - - - EA 加入購(gòu)物車
源葉(MedMol) S81341-10mg ≥96% ¥1185.00元 10 - - - EA 加入購(gòu)物車
源葉(MedMol) S81341-25mg ≥96% ¥1625.00元 7 - - - EA 加入購(gòu)物車
源葉(MedMol) S81341-50mg ≥96% ¥2817.00元 6 - - - EA 加入購(gòu)物車
源葉(MedMol) S81341-100mg ≥96% ¥4789.00元 5 - - - EA 加入購(gòu)物車
大包裝詢價(jià)

提交您的電話號(hào)碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 提示:詳情請(qǐng)下載說(shuō)明書。
  • 產(chǎn)品描述: Naquotinib (ASP8273) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.
  • 靶點(diǎn): EGFR:230 nM (IC50);EGFRT790M;EGFRL858R/T790M;EGFRL858R;EGFRExon 19 deletion/T790M;EGFR
  • 體外研究:
    In assays using endogenously EGFR-dependent cells, Naquotinib inhibits the growth of PC-9(del ex19), HCC827(del ex19), NCI-H1975(del ex19/T790M) and PC-9ER(del ex19/T790M) with IC50s of 8-33 nM. Naquotinib selectively inhibits phosphorylation of EGFR and its down-stream signal pathway, ERK and Akt from 10nM in HCC827 and NCI-H1975 while inhibitory effects are only detected at 1000nM in A431.In NCI-H1650 (del ex19), Naquotinib inhibits cell growth with an IC50 value of 70nM while other EGFR-TKIs are only partially effective
  • 體內(nèi)研究:
    Oral Naquotinib treatment dose dependently induces tumor regression in NCI-H1975 (L858R/T790M), HCC827 (del ex19) and PC-9 (del ex19) xenograft models. Dosing schedules does not affect the efficacy of Naquotinib. In an NCI-H1975 xenograft model, complete regression of tumor is achieved after 14-days of Naquotinib treatment. Complete regression is maintained in 50% of mice more than 85 days after cessation of Naquotinib treatment
  • 參考文獻(xiàn):
    1. Sakagami H, et al. ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1728. doi:10.1158/1538-7445.AM2014-1728 2. Konagai S, et al. ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Ph
  • 溶解性: Soluble  in  DMSO、Ethanol
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 1.777 ml 8.886 ml 17.771 ml
    5 mM 0.355 ml 1.777 ml 3.554 ml
    10 mM 0.178 ml 0.889 ml 1.777 ml
    50 mM 0.036 ml 0.178 ml 0.355 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。